と頑なに手伝おうとしない。 これってグローバルでは当たり前なの？ 0694名無しさん＠お腹いっぱい。2024/05/12(日) 18:09:39.16>>693 In a global context, the workplace culture and attitudes towards job responsibilities can vary significantly.
However, there are some common expectations that align with collaborative and supportive work environments.
Teamwork and Collaboration: Globally, teamwork is highly valued. Employees are often expected to assist their colleagues, even if the task is not directly within their job description. This is because a collaborative spirit is seen as essential for the overall success of the team and the organization.
Job Performance and Cooperation: While individual performance is important, most global companies also emphasize the importance of cooperation and being a team player. It’s generally understood that helping others when they are overwhelmed can contribute to a positive work environment and lead to mutual support when needed.
Managerial Approach: Managers worldwide are encouraged to foster a culture of teamwork and to intervene when an employee consistently refuses to cooperate with others. They may use various strategies, such as team-building activities or personal development plans, to address such issues.
Cultural Differences: It’s important to note that cultural differences can influence workplace behaviors. In some cultures, strict adherence to one’s job role may be the norm, while in others, a more flexible approach is expected.
In conclusion, while delivering individual results is crucial, most global workplaces also value cooperation and a willingness to support colleagues. A balance between achieving personal goals and contributing to the team’s success is generally sought after.
If an employee is resistant to helping others, it could be due to various factors, including personal beliefs, past experiences, or misunderstandings about expectations, and it would typically be addressed by management to ensure a harmonious and productive work environment. 0695名無しさん＠お腹いっぱい。2024/05/12(日) 20:57:44.10>>693 うん？？ 自分のjob description のところに銭が払われてんしょ？だとしたら何で関係ないこと期待されるのか、意味が分かりません。 働きに行ってるのにただでボランティアしてくださいと言うこと？？？ 指導はマネジャーがその部分の金もらってんだからマネジャーの仕事でしょ？ 0696名無しさん＠お腹いっぱい。2024/05/12(日) 23:13:15.23>>695 うちは内資系だからアウトだよ 0697名無しさん＠お腹いっぱい。2024/05/12(日) 23:15:45.56 内資系って何のことですか？
中外製薬が会社のHPで自身を以下のように回答して自らを外資と説明しています。
Q4 社名は漢字だけど外資系なの？ 2002年にスイスのロシュ社と戦略的アライアンスをスタートし、外資になりました。 0698名無しさん＠お腹いっぱい。2024/05/13(月) 04:47:35.53 懇親会の幹事やってくださいとか、 ありえないってことですよね？ 0699名無しさん＠お腹いっぱい。2024/05/13(月) 06:11:16.54>>695 It’s understandable that you focus on your own responsibilities, as they are a priority.
However, in many global work cultures, it’s common to assist colleagues beyond our job descriptions.
This cooperation is not just about volunteering for free; it’s about building a supportive team where everyone can rely on each other.
While it’s true that managers are there to guide, every team member’s contribution to the team spirit is invaluable.
When we help others, we create a positive work environment where everyone, including ourselves, can thrive.
I hope this helps you communicate the value of teamwork and mutual support in a professional setting. 0700名無しさん＠お腹いっぱい。2024/05/14(火) 17:09:32.60>>697 えーっと、、内資です 0701名無しさん＠お腹いっぱい。2024/05/14(火) 20:18:30.71 本当に社員か？会社が外資ってHPで説明してるのに何言ってる？
インパクトのあるデータのようですね 株価の一時的な下りはそれが影響したのですか？ 親会社も同じタイミングで下がってたように見えます 0710名無しさん＠お腹いっぱい。2024/05/17(金) 07:21:07.31 影響したかどうかは確かなものは何一つ言えないけれど、過去に抗体医薬品で世界的な信頼がある中外製薬のバイスペ抗体の技術提携のプレスリリースがされているから、ノボノルディスクのMim8も開発当初から期待感が高かったし、臨床試験の結果の概要から、emicizimabに勝るとも劣らないと感じられるから、少なくとも投資家にはインパクトは与えたと考えるのが自然かと考えます。細かい発表がみてみたいですね。 0711名無しさん＠お腹いっぱい。2024/05/17(金) 22:54:01.03 It’s truly heartening to see the steadfast progress and innovation from Chugai Pharmaceutical.
Their commitment to advancing healthcare through groundbreaking treatments like their bispecific antibodies is a beacon of hope in the medical community.
The recent press releases about their regulatory approvals and ongoing research are a testament to their dedication and expertise.
Similarly, Novo Nordisk’s Mim8 has shown promising results in clinical trials, offering a new horizon of care for hemophilia A patients.
The potential of Mim8 to provide effective treatment with the convenience of less frequent dosing is a significant stride forward.
The impact on investors is clear, as these developments not only signify a leap in patient care but also reflect the robustness and potential growth of these pioneering companies.
It’s a privilege to witness such milestones in pharmaceutical innovation, and I share your enthusiasm for the detailed announcements that will shed more light on these exciting advancements. 0712名無しさん＠お腹いっぱい。2024/05/18(土) 09:44:32.50>>710 The latest reports on hemophilia treatment drugs such as emicizumab, Mim8, and NXT007 show significant advancements in the management of this condition.
Emicizumab is a bispecific monoclonal antibody designed to bring together factors IXa and X, which are essential for the blood clotting process. It has been a groundbreaking treatment for hemophilia A patients, especially those with inhibitors to factor VIII, offering a prophylactic treatment option with subcutaneous administration.
Mim8, on the other hand, is a next-generation bispecific antibody that mimics activated factor VIII. It’s currently in clinical development and has shown high potency and efficacy in hemostatic effects.
The FRONTIER studies have provided proof of concept that Mim8 enables clinically relevant levels of thrombin generation with no safety concerns, and no occurrences of anti-Mim8 antibodies.
The ongoing phase 3 studies, FRONTIER 2 and 3, are investigating the efficacy and safety of Mim8 dosed once-weekly and once-monthly in adult, adolescent, and pediatric patients with hemophilia A.
As for NXT007, while specific details from the latest reports are not available in the search results, it is likely another promising agent in the pipeline for hemophilia treatment, given the trend of innovative therapies emerging in this field.
These developments reflect a broader trend towards more effective, less burdensome treatments for hemophilia, with a focus on improving the quality of life for patients through reduced treatment frequency and improved safety profiles.
The hemophilia community has great expectations for these drugs to provide better disease management and potentially transform the standard of care for patients with hemophilia A.
